Unknown

Dataset Information

0

Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults.


ABSTRACT: We explored whether acute atorvastatin treatment would improve clinical outcomes and reduce the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage in elderly Chinese adults. Patients (60 to 90 years old) were admitted to intensive care units after surgery to clip or embolize their aneurysms. We assessed 592 patients and assigned 159 to receive atorvastatin (20 mg/day) and 158 to receive placebo once daily for up to 14 days. The primary outcome was the Glasgow outcome scale at 6 months, and secondary outcomes were cerebral vasospasm, 30-days all-cause mortality, cerebral infarction, and delayed ischemic neurological deficit. The incidence of postoperative cerebral vasospasm (39.3% vs 56%, P =0.004) and cerebral infarction (18.7% vs 27.3%, P=0.027) were significantly lower in the atorvastatin group. The study did not detect benefits in the use of atorvastatin for 6 months clinical outcome or 30-day all-cause mortality, but it suggests that atorvastatin together with nimodipine can reduce cerebral vasospasm and cerebral infarction after subarachnoid hemorrhage.

SUBMITTER: Chen J 

PROVIDER: S-EPMC7041764 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults.

Chen Junhui J   Li Mingchang M   Zhu Xun X   Chen Lei L   Yang Shuo S   Zhang Chunlei C   Wu Ting T   Feng Xiaoyan X   Wang Yuhai Y   Chen Qianxue Q  

Aging 20200207 3


We explored whether acute atorvastatin treatment would improve clinical outcomes and reduce the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage in elderly Chinese adults. Patients (60 to 90 years old) were admitted to intensive care units after surgery to clip or embolize their aneurysms. We assessed 592 patients and assigned 159 to receive atorvastatin (20 mg/day) and 158 to receive placebo once daily for up to 14 days. The primary outcome was the Glasgow outcome scale  ...[more]

Similar Datasets

| S-EPMC5158085 | biostudies-literature
| S-EPMC3271157 | biostudies-literature
2014-05-08 | E-GEOD-37924 | biostudies-arrayexpress
2014-05-08 | GSE37924 | GEO
| S-EPMC5573230 | biostudies-other
| S-EPMC2773037 | biostudies-other
2021-06-02 | GSE165608 | GEO
| S-EPMC5533026 | biostudies-literature
| S-EPMC8163224 | biostudies-literature